Active Ingredient History
CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acquired Immunodeficiency Syndrome (Phase 4)
Acute-On-Chronic Liver Failure (Phase 4)
Aicardi Syndrome (Phase 1/Phase 2)
AIDS-Related Opportunistic Infections (Phase 4)
Alcohol-Induced Disorders (Phase 4)
Alveolar Bone Loss (Phase 4)
Amphetamine-Related Disorders (Phase 2)
Analgesics, Opioid (Phase 4)
Anesthesia (Phase 4)
Anti-Infective Agents (Phase 1)
Anti-Retroviral Agents (Phase 2)
Antiretroviral Therapy, Highly Active (Phase 4)
Art (Phase 3)
Atazanavir Sulfate (Phase 1)
Atherosclerosis (Phase 2)
Behavior and Behavior Mechanisms (Phase 1/Phase 2)
Body Weight Changes (Phase 3)
Bone Diseases (Phase 4)
Bone Diseases, Metabolic (Phase 4)
Breast Feeding (Phase 3)
Carcinoma, Hepatocellular (Phase 4)
Cardiovascular Diseases (Phase 4)
Central Nervous System (Phase 2)
Central Nervous System Diseases (Phase 4)
Chlamydia (Phase 3)
Cognition Disorders (Phase 4)
Communicable Diseases (Phase 2)
Congenital Abnormalities (Phase 4)
Contraception (Phase 2)
Contraception Behavior (Phase 1)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 3)
Dementia (Phase 4)
Depression (Phase 4)
Drug Evaluation (Phase 1/Phase 2)
Drug Interactions (Phase 1)
Drug Misuse (Early Phase 1)
Drugs, Investigational (Phase 4)
Dyslipidemias (Phase 4)
Estrogens (Phase 4)
Fasting (Phase 3)
Fatty Liver (Phase 4)
Fibrosis (Phase 4)
Gender Dysphoria (Phase 1)
Gender Identity (Phase 1/Phase 2)
Gonorrhea (Phase 3)
Healthy Volunteers (Phase 4)
Hepacivirus (Phase 1)
Hepatitis (Phase 1)
Hepatitis B (Phase 2)
Hepatitis B virus (Phase 4)
Hepatitis C (Phase 4)
Hepatitis C, Chronic (Phase 3)
Hepatitis, Chronic (Phase 4)
Hepatitis D (Phase 2)
Hepatitis D, Chronic (Phase 3)
Herpes Genitalis (Phase 4)
HIV (Phase 4)
HIV-1 (Phase 4)
HIV-Associated Lipodystrophy Syndrome (Phase 4)
HIV Seronegativity (Phase 2/Phase 3)
HIV Seropositivity (Phase 2)
Hormones (Phase 4)
Infections ()
Insulin Resistance (Phase 1)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 1)
Lipodystrophy (Phase 2)
Liver Cirrhosis (Phase 4)
Liver Cirrhosis, Biliary (Phase 2)
Liver Diseases (Phase 1)
Lung Diseases (Phase 1)
Lung Transplantation (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 4)
Malaria (Phase 3)
Medication Adherence (Phase 4)
Menopause (Phase 4)
Metabolic Diseases (Phase 4)
Metabolic Syndrome (Phase 3)
Minority Health (Phase 3)
Mitochondrial Diseases (Phase 1/Phase 2)
Multiple Sclerosis (Phase 2)
Neoplasms (Phase 4)
Nutrition Disorders (Phase 2)
Obesity (Phase 4)
Opioid-Related Disorders (Phase 4)
Organ Transplantation (Phase 4)
Osteoporosis (Phase 4)
Parasitic Diseases (Phase 1/Phase 2)
Patient Acceptance of Health Care (Phase 2)
Patient Compliance (Phase 4)
Persistent Infection (Phase 4)
Pharmacokinetics (Phase 1/Phase 2)
Pre-Exposure Prophylaxis (Phase 4)
Pregnancy (Phase 4)
Proteinuria (Phase 4)
Quality of Life (Phase 4)
Rectum (Phase 1)
Renal Insufficiency (Phase 4)
Respiratory Tract Infections (Phase 1/Phase 2)
Risk Factors (Phase 1)
Risk Reduction Behavior (Phase 4)
Risk-Taking (Phase 4)
Safety (Phase 1/Phase 2)
Sarcoma, Kaposi (Phase 4)
SARS-CoV-2 (Phase 2/Phase 3)
Sexual Behavior (Phase 4)
Sexually Transmitted Diseases (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Sleep Wake Disorders (Phase 4)
Substance Abuse, Oral (Phase 2)
Substance-Related Disorders (Phase 4)
Syphilis (Phase 4)
Tenofovir (Phase 4)
Therapeutics (Phase 1)
Transgender Persons (Phase 4)
Tuberculosis (Phase 4)
Tuberculosis, Multidrug-Resistant (Phase 1)
Tuberculosis, Pulmonary (Phase 1)
Vascular Diseases (Phase 2)
Viremia (Phase 4)
Weight Gain (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue